RU2223784C2 - Живая вакцина против вируса иммунодефицита человека - Google Patents

Живая вакцина против вируса иммунодефицита человека Download PDF

Info

Publication number
RU2223784C2
RU2223784C2 RU2000123173/15A RU2000123173A RU2223784C2 RU 2223784 C2 RU2223784 C2 RU 2223784C2 RU 2000123173/15 A RU2000123173/15 A RU 2000123173/15A RU 2000123173 A RU2000123173 A RU 2000123173A RU 2223784 C2 RU2223784 C2 RU 2223784C2
Authority
RU
Russia
Prior art keywords
immunodeficiency virus
human immunodeficiency
protein
specified
vaccine
Prior art date
Application number
RU2000123173/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2000123173A (ru
Inventor
Мэри Сьюзан БЕРНЕТТ (US)
Мэри Сьюзан БЕРНЕТТ
Джордж Барри КИТТО (US)
Джордж Барри КИТТО
Original Assignee
Рисерч Дивелопмент Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рисерч Дивелопмент Фаундейшн filed Critical Рисерч Дивелопмент Фаундейшн
Publication of RU2000123173A publication Critical patent/RU2000123173A/ru
Application granted granted Critical
Publication of RU2223784C2 publication Critical patent/RU2223784C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • External Artificial Organs (AREA)
RU2000123173/15A 1998-02-06 1999-02-04 Живая вакцина против вируса иммунодефицита человека RU2223784C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7394398P 1998-02-06 1998-02-06
US60/073,943 1998-02-06

Publications (2)

Publication Number Publication Date
RU2000123173A RU2000123173A (ru) 2002-11-10
RU2223784C2 true RU2223784C2 (ru) 2004-02-20

Family

ID=22116747

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000123173/15A RU2223784C2 (ru) 1998-02-06 1999-02-04 Живая вакцина против вируса иммунодефицита человека

Country Status (13)

Country Link
EP (1) EP1061950B1 (enExample)
JP (1) JP2002502827A (enExample)
KR (1) KR20010040618A (enExample)
CN (1) CN1216640C (enExample)
AT (1) ATE287727T1 (enExample)
AU (1) AU744730B2 (enExample)
CA (1) CA2320489A1 (enExample)
DE (1) DE69923439D1 (enExample)
IL (1) IL137680A0 (enExample)
NZ (1) NZ506093A (enExample)
RU (1) RU2223784C2 (enExample)
WO (1) WO1999039735A1 (enExample)
ZA (1) ZA99912B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2802426B1 (fr) 1999-12-15 2004-04-02 Neovacs Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires
AU8640501A (en) * 2000-07-31 2002-02-13 Univ Yale Innate immune system-directed vaccines
KR100447530B1 (ko) * 2001-08-14 2004-09-08 한국과학기술원 ＯｍｐＦ를 이용하여 목적 단백질을 대장균 세포외로분비생산하는 방법
EP1670505B1 (en) 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna promoters and anthrax vaccines
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
CN101195823B (zh) * 2007-11-20 2010-06-02 华东理工大学 细菌表面展示系统、方法及应用
CN109207417A (zh) * 2018-09-19 2019-01-15 湖北省农业科学院畜牧兽医研究所 鸡白痢-j亚群禽白血病双重平板凝集抗原及其制备方法
JP2023516420A (ja) * 2020-03-05 2023-04-19 ユニヴァーシティー オブ メリーランド バルチモア がんタンパク質抗原を発現するように操作された生チフス菌ベクターおよびその使用方法
WO2025063261A1 (ja) * 2023-09-22 2025-03-27 塩野義製薬株式会社 ウイルス由来タンパク質をコードするポリヌクレオチド

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725864A (en) * 1992-07-28 1998-03-10 Snow Brand Milk Products Co., Ltd. Composition for suppressing infection and growth of human immunodeficiency virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757013A (en) * 1983-07-25 1988-07-12 The Research Foundation Of State University Of New York Cloning vehicles for polypeptide expression in microbial hosts
AU9179891A (en) * 1990-12-19 1992-07-22 Epitope, Inc. Hiv reverse transcriptase vaccine
AU3958895A (en) * 1994-10-18 1996-05-06 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725864A (en) * 1992-07-28 1998-03-10 Snow Brand Milk Products Co., Ltd. Composition for suppressing infection and growth of human immunodeficiency virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Биохимия гормонов и гормональная регуляция/Под ред. Н.А.Юдаева. - М.: Наука, 1976, стр.192-208. *

Also Published As

Publication number Publication date
DE69923439D1 (de) 2005-03-03
ATE287727T1 (de) 2005-02-15
AU744730B2 (en) 2002-02-28
CA2320489A1 (en) 1999-08-12
IL137680A0 (en) 2001-10-31
KR20010040618A (ko) 2001-05-15
AU3180199A (en) 1999-08-23
NZ506093A (en) 2003-08-29
EP1061950A1 (en) 2000-12-27
CN1216640C (zh) 2005-08-31
WO1999039735A9 (en) 2000-01-27
EP1061950A4 (en) 2001-12-05
EP1061950B1 (en) 2005-01-26
WO1999039735A1 (en) 1999-08-12
JP2002502827A (ja) 2002-01-29
CN1290175A (zh) 2001-04-04
ZA99912B (en) 2000-08-07

Similar Documents

Publication Publication Date Title
ES2139879T5 (es) Adyuvante de la mucosa no toxico.
CA2102918C (en) Genetic vaccine for immunodeficiency viruses
Shata et al. Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8+ T cells and antiviral protective immunity
Hamajima et al. Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response
Monteiro-Maia et al. Oral bacillus Calmette-Guérin vaccine against tuberculosis: why not?
Hinkula et al. Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses
Yao et al. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity
Liu et al. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model
Kim et al. The immune response induced by DNA vaccine expressing nfa1 gene against Naegleria fowleri
Pang et al. Truncated flagellin lacking the hypervariable region: a structural basis for improved immune responses and adjuvanticity
Stevceva et al. Mucosal HIV vaccines: where are we now?
Yoshino et al. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates
JPH06165689A (ja) 組換えアデノウイルスワクチン
RU2000123173A (ru) Живая вакцина против вируса иммунодефицита человека
AU744730B2 (en) Live vaccine for human immunodeficiency virus
Yuki et al. Progress towards an AIDS mucosal vaccine: an overview
Chin et al. Effective mucosal adjuvantation of the intranasal enterovirus A71 vaccine with zymosan
JP2002502827A5 (enExample)
Bourinbaiar et al. Mucosal AIDS vaccines
Lásaro et al. Combined vaccine regimen based on parenteral priming with a DNA vaccine and administration of an oral booster consisting of a recombinant Salmonella enterica serovar Typhimurium vaccine strain for immunization against infection with human-derived enterotoxigenic Escherichia coli strains
Tafuku et al. Japanese encephalitis virus structural and nonstructural proteins expressed in Escherichia coli induce protective immunity in mice
Stokes et al. Mucosal infection and vaccination against feline immunodeficiency virus
O’Donovan et al. A vector expressing feline mature IL-18 fused to IL-1β antagonist protein signal sequence is an effective adjuvant to a DNA vaccine for feline leukaemia virus
US7189402B1 (en) Live vaccine for human immunodeficiency virus
RU2840971C1 (ru) Способ создания рекомбинантного штамма энтерококка L3-SARS"XBB.1.5" на основе биологически активного штамма Enterococcus faecium L3

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090205